14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026
CAMP vs OMER: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 17, 2026, Omeros Corporation (OMER) is the stronger overall head-to-head candidate over CAMP4 Therapeutics Corporation (CAMP) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). CAMP carries a Unified Composite Score of 43.9/100 (HOLD) at $3.95 (N/M Forward P/E, -991.8% operating margin), whereas OMER carries 50.8/100 (HOLD) at $13.70 (73.0x Forward P/E, -189.5% operating margin).
Growth vs. Quality Trade-Off: OMER earns the overall head-to-head edge with a stronger Unified Composite Score (50.8/100 HOLD vs. CAMP 43.9/100 HOLD) and 1.97β · 81% Vol risk profile, whereas CAMP leads top-line expansion (+138.9% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates.
Technical & Structure Timing Caution: CAMP trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 51.9); meanwhile OMER is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 30.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Competes within the Biotechnology value chain with $1.3B market capitalization and -189.5% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ CAMP vs OMER Key Questions & Quantitative Answers
As of Nov 17, 2026, Omeros Corporation (OMER) is the stronger overall head-to-head candidate over CAMP4 Therapeutics Corporation (CAMP) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). CAMP carries a Unified Composite Score of 43.9/100 (HOLD) at $3.95 (N/M Forward P/E, -991.8% operating margin), whereas OMER carries 50.8/100 (HOLD) at $13.70 (73.0x Forward P/E, -189.5% operating margin). Growth vs. Quality Trade-Off: OMER earns the overall head-to-head edge with a stronger Unified Composite Score (50.8/100 HOLD vs. CAMP 43.9/100 HOLD) and 1.97β · 81% Vol risk profile, whereas CAMP leads top-line expansion (+138.9% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: CAMP trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 51.9); meanwhile OMER is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 30.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
OMER leads the Growth & Scale pillar: CAMP posts +138.9% YoY revenue growth and +0.0% YoY earnings growth on $5.3M TTM revenue (N/A gross margin, -991.8% operating margin), compared with OMER at +14.9% YoY revenue growth and +0.0% YoY earnings growth on $27M TTM revenue (38.3% gross margin, -189.5% operating margin). Across the 8-period historical trajectory (FY2016 to FY2025), CAMP cumulative revenue shifted N/A while OMER shifted +75.0%. In operating R&D and SG&A reinvestment, CAMP deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for OMER.
OMER screens cheaper on headline valuation multiples. CAMP trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 26.6x EV/Revenue (unreported FCF margin), whereas OMER trades at 73.0x Forward P/E, 14.3x Trailing P/E, 0.81x PEG, and 50.1x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CAMP (-146.1% ROE) versus OMER (-576.3% ROE) capital efficiency.
In options market volatility and institutional positioning, CAMP carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.34β · 94% Vol realized risk). By comparison, OMER carries 85.5% implied volatility (28th %ile, Balanced (25th–60th %ile)), a 0.18x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.97β · 81% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.